NCAM1 and small cell lung carcinoma: Altogether, these observations support the hypothesis that CD56+ CTC can reliably recapitulate the mutational status of treatment-naive SCLC tumors and may represent a comprehensive way of capturing the whole mutational picture of SCLC.